A separate study found that abiraterone plus androgen deprivation therapy was superior to androgen deprivation therapy in prostate cancer not previously treated with hormone therapy.
Abiraterone is currently licensed for use in metastatic castration resistant prostate cancer after failure of androgen therapy in patients in whom chemotherapy is not yet clinically indicated, and in metastatic castration resistant prostate cancer in patients whose disease has progressed on or after a docetaxel based chemotherapy regimen.
NICE TA259 recommends abiraterone for in combination with prednisone or prednisolone is d as an option for the treatment of castration resistant metastatic prostate cancer in adults whose disease has progressed on or after one docetaxel-containing chemotherapy regimen.
NICE TA387 recommends abiraterone in combination with prednisone or prednisolone as an option for metastatic hormone-relapsed prostate cancer in people who have no or mild symptoms after androgen deprivation therapy has failed and before chemotherapy is indicated.